Co-Sponsors Highlight Important Research from the 2012 Genitourinary Cancers Symposium

ALEXANDRIA, Va. – Eight noteworthy abstracts from the 2012 Genitourinary Cancers Symposium will focus on the late effects of prostate cancer treatment, as well as new treatments for prostate and kidney cancers. The findings will be presented during this year’s Symposium, which takes place February 2-4 in San Francisco.

Abstract # 6
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics
Oral Abstract Session A: Prostate Cancer
Thursday, February 2
Yerba Buena Ballroom, Salon 8
2:05-2:15 PM PT

Abstract # 18
Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08.
General Poster Session A: Prostate Cancer
Thursday, February 2
Golden Gate Hall
Poster B3
11:45 AM-1:15 PM PT

Abstract # 356
Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2.
General Poster Session E: Renal Cancer
Saturday, February 4
Golden Gate Hall
Poster A9
11:50 AM-1:05 PM PT

Abstract # 186
Biochemical, pathologic, toxicity, and quality-of-life outcomes in a five-fraction hypofractionated accelerated radiotherapy treatment using standard linear accelerators and gold seed fiducials.
General Poster Session C: Prostate Cancer
Friday, February 3
Golden Gate Hall
Poster B6
12:15-1:45 PM PT

Abstract # 101
Prevalence and characteristics of patients with metastatic prostate cancer who receive no anticancer therapy.
General Poster Session B: Prostate Cancer
Thursday, February 2
Golden Gate Hall
Poster A6
5:05-6:35 PM PT

Abstract # 354
Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
Oral Abstract Session C: Renal Cancer
Saturday, February 4
Yerba Buena Ballroom, Salon 8
11:00-11:10 AM PT

Abstract # 181
Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer.
General Poster Session C: Prostate Cancer
Friday, February 3
Golden Gate Hall
Poster B1
12:15-1:45 PM PT

Abstract # 353
A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.
Oral Abstract Session C: Renal Cancer
Saturday, February 4
Yerba Buena Ballroom, Salon 8
10:50-11:00 AM PT

To view the full release click here.